Hemlibra_Emicizumab_ Summary of product characteristics v1
Hemlibra_Emicizumab_ Summary of product characteristics v1
Hemlibra_Emicizumab_ Public assessment summary reportv1
Hemlibra_Emicizumab_ Public assessment summary reportv1
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_public assessment summary report
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics
Lumerax DT 20120_ Artemether 20 mg & Lumefantrine 120 mg Dispersible_Summary of product characteristics
INIGAST 40 Public assessment summary report v1
INIGAST 40 Public assessment summary report v1
INIGAST 40 Summary of product characteristics v1
INIGAST 40 Summary of product characteristics v1
ALLTERA 50 Summary of product characteristics v1
ALLTERA 50 Summary of product characteristics v1
ALLTERA 50 Public assessment summary report v1
ALLTERA 50 Public assessment summary report v1
Food and Medicine Administration Proclamation No.1112/2019
Food and Medicine Administration Proclamation 1112